| Study Details | To evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who are naïve to complement inhibitor therapy |
| Protocol Number | CLNP023C12301 |
| Phase | III |
| Therapeutic Area | Haematology |
| Subject Types | With Medical Condition |
| Indication | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Principal Investigator | Dr Yap Eng Soo |
| Investigator Product / Device | iptacopan |
| Sponsor | Novartis (Singapore) Pte Ltd |
